231 Meta-analysis female sex and mortality in SAB 10 77. Rieg S, Peyerl-Hoffmann G, de With K, et al. Mortality of S. aureus bacteremia and infectious diseases specialist consultation–a study of 521 patients in Germany. J Infect. 2009;59(4):232-239. 78. Roth JA, Widmer AF, Tschudin-Sutter S, et al. The Model for End-stage Liver Disease (MELD) as a predictor of short-term mortality in Staphylococcus aureus bloodstream infection: a single-centre observational study. PLoS One. 2017;12(4):e0175669. 79. Saunderson RB, Gouliouris T, Nickerson EK, et al. Impact of routine bedside infectious disease consultation on clinical management and outcome of Staphylococcus aureus bacteraemia in adults. Clin Microbiol Infect. 2015;21 (8):779-785. 80. Schneider SM, Schaeg M, Gärtner BC, Berger FK, Becker SL. Do written diagnosistreatment recommendations on microbiological test reports improve the management of Staphylococcus aureus bacteremia? a single-center, retrospective, observational study. Diagn Microbiol Infect Dis. 2020;98(4):115170. 81. Seas C, Garcia C, Salles MJ, et al; Latin America Working Group on Bacterial Resistance. Staphylococcus aureus bloodstream infections in Latin America: results of a multinational prospective cohort study. J Antimicrob Chemother. 2018;73(1):212-222. 82. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193-200. 83. Soriano A, Martínez JA, Mensa J, et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis. 2000;30(2):368-373. 84. Sullivan SB, Austin ED, Stump S, et al. Reduced vancomycin susceptibility of methicillinsusceptible Staphylococcus aureus has no significant impact on mortality but results in an increase in complicated infection. Antimicrob Agents Chemother. 2017;61(7):e0031617. 85. Szubert A, Bailey SL, Cooke GS, et al; United Kingdom Clinical Infection Research Group (UKCIRG). Predictors of recurrence, early treatment failure and death from Staphylococcus aureus bacteraemia: Observational analyses within the ARREST trial. J Infect. 2019;79(4):332-340. 86. Tan K, Minejima E, Lou M, Mack WJ, Nieberg P, Wong-Beringer A. Cytokine measurements add value to clinical variables in predicting outcomes for Staphylococcus aureus bacteremia. BMC Infect Dis. 2021;21(1):317. 87. Ternavasio-de la Vega HG, Castaño-Romero F, Ragozzino S, et al. The updated Charlson comorbidity index is a useful predictor of mortality in patients with Staphylococcus aureus bacteraemia. Epidemiol Infect. 2018;146(16): 2122-2130. 88. Thorlacius-Ussing L, Sandholdt H, Larsen AR, Petersen A, Benfield T. Age-dependent increase in incidence of Staphylococcus aureus bacteremia, Denmark, 2008-2015. Emerg Infect Dis. 2019;25(5):875-882. 89. Thwaites GE; United Kingdom Clinical Infection Research Group (UKCIRG). The management of Staphylococcus aureus bacteremia in the United Kingdom and Vietnam: a multi-centre evaluation. PLoS One. 2010;5(12):e14170. 90. Tong SY, van Hal SJ, Einsiedel L, Currie BJ, Turnidge JD; Australian New Zealand Cooperative on Outcomes in Staphylococcal Sepsis. Impact of ethnicity and socioeconomic status on Staphylococcus aureus bacteremia incidence and mortality: a heavy burden in Indigenous Australians. BMC Infect Dis. 2012;12:249. 91. Turnidge JD, Kotsanas D, Munckhof W, et al; Australia New Zealand Cooperative on Outcomes in Staphylococcal Sepsis. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust. 2009;191(7):368-373.
RkJQdWJsaXNoZXIy MTk4NDMw